Medifast (MED) Up 6.5% Since Last Earnings Report: Can It Continue?

Medifast (MED) reported Q2 2025 results exceeding consensus estimates, with adjusted EPS of $0.04 and revenues of $105.6 million, yet both metrics declined significantly year-over-year by 37.4% in revenue and a sharp drop in EPS. This downturn is primarily attributed to a 32.7% reduction in active OPTAVIA coaches and pressures from GLP-1 medication adoption, highlighting structural challenges. Despite a recent 6.5% stock gain, the company's weak Q3 2025 outlook, projecting revenues of $70-$90 million and a potential loss, has led to downward revisions in analyst estimates and a Zacks Rank #4 (Sell) rating.

Analysis

Medifast's recent 6.5% share price appreciation is incongruous with its deteriorating operational and financial fundamentals. While the company's Q2 2025 revenue of $105.6 million and adjusted EPS of four cents surpassed suppressed consensus estimates, these figures mask a severe year-over-year contraction, with revenue plummeting 37.4% and adjusted earnings collapsing from the prior year's 92 cents per share. The core of the business model is under significant pressure, evidenced by a 32.7% plunge in active OPTAVIA coaches and a 6.9% decline in average revenue per coach. This downturn is attributed to persistent client acquisition challenges and, critically, the competitive threat from the rapid adoption of GLP-1 weight-loss medications. The company's forward guidance for Q3 signals further decline, with revenues projected to fall to between $70 million and $90 million and the bottom line swinging to a loss of up to $0.60 per share. Consequently, analyst estimates have been revised downward by 116.67%, leading to a Zacks Rank #4 (Sell). While a strong balance sheet with $162.7 million in cash and no debt provides a cushion, it does not negate the structural threats and the sharply negative outlook.

Key Decisions for Investors

• Investors should treat the recent 6.5% stock rally with extreme caution, as it starkly contrasts with the severe 37.4% year-over-year revenue decline and a deeply negative forward outlook.
• The primary focus for due diligence should be on the company's ability to stabilize its declining base of OPTAVIA coaches, which fell 32.7%, as this metric is the core driver of revenue and faces structural headwinds from GLP-1 medications.
• The aggressive downward revisions in analyst estimates and the company's own guidance for a Q3 net loss of up to $0.60 per share signal significant near-term risk that potentially outweighs the comfort provided by its debt-free balance sheet.